Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy

Background and purpose We have previously shown that patients with multiple sclerosis receiving immunomodulatory treatment have reduced seroprotection rates after influenza immunization. The aim of this study was to further investigate the influence of immunomodulatory therapies on the antibody resp...

Full description

Saved in:
Bibliographic Details
Published in:European journal of neurology 2018-03, Vol.25 (3), p.527-534
Main Authors: Olberg, H. K., Eide, G. E., Cox, R. J., Jul‐Larsen, Å., Lartey, S. L., Vedeler, C. A., Myhr, K.‐M.
Format: Article
Language:English
Subjects:
Adult
Antibodies, Viral - blood
Antibody response
Copolymer 1
Female
Fingolimod Hydrochloride - pharmacology
Glatiramer Acetate - pharmacology
Hemagglutination inhibition
Humans
Immunization
Immunogenicity, Vaccine - immunology
Immunologic Factors - pharmacology
Immunomodulation
immunotherapy
Influenza
Influenza Vaccines - immunology
Interferon
Interferon beta-1b - pharmacology
Male
Middle Aged
Monoclonal antibodies
Multiple sclerosis
Multiple Sclerosis - drug therapy
Multiple Sclerosis - immunology
Natalizumab - pharmacology
Patients
protection
seasonal influenza vaccination
Seasons
Therapy
Vaccination
Vaccines
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and purpose We have previously shown that patients with multiple sclerosis receiving immunomodulatory treatment have reduced seroprotection rates after influenza immunization. The aim of this study was to further investigate the influence of immunomodulatory therapies on the antibody response and seroprotection rates in patients immunized with seasonal influenza vaccine in 2012/2013 compared with healthy controls. Methods Ninety patients receiving fingolimod, glatiramer acetate, interferon beta‐1a/1b, natalizumab or no therapy were compared with 62 healthy controls. All subjects received the inactivated split virus vaccine in 2012 and serum samples were collected pre‐vaccination and 3, 6 and 12 months post‐vaccination. The vaccine responses were evaluated by the hemagglutination inhibition assay and adjusted for age and gender. Results No significant differences in rates of protection against H1N1 for interferon beta‐1a/1b and glatiramer acetate were observed as compared with controls at 3, 6 and 12 months. Fingolimod provided reduced protection at all time points post‐vaccination, whereas natalizumab displayed reduced protection at 3 and 6 months. Patients without immunomodulation did not display protection rates that were significantly different from the controls at 3 and 12 months. Conclusion These findings suggest that patients with multiple sclerosis receiving fingolimod or natalizumab should be considered for a second dose of the vaccine in cases of insufficient protection. Our results further indicate that new immunomodulatory treatment regimens should be systematically evaluated for their influence on influenza‐specific vaccine responses.
ISSN:1351-5101
1468-1331
DOI:10.1111/ene.13537